Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IXO regimen in locally advanced rectal cancer
NCT01237665Phase 2Unknown
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Sep 2010
- Primary completion
- Dec 2012
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan, capecitabine, oxaliplatin in rectal cancer, sponsored by Ottawa Hospital Research Institute. Status: unknown.
02
Drugs
irinotecancapecitabineoxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT01237665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01237665.